UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 85

Sortiert nach

Apremilast, a cAMP phosphodiesterase‐4 inhibitor, demonstrates anti‐inflammatory activity in vitro and in a model of psoriasis

British journal of pharmacology, 2010-02, Vol.159 (4), p.842-855

2010

Volltextzugriff (PDF)

Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications

Leukemia, 2001-12, Vol.15 (12), p.1950-1961

2001

Volltextzugriff (PDF)

Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy

Blood, 2000-11, Vol.96 (9), p.2943-2950

2000

Volltextzugriff (PDF)

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma

Blood, 2004-12, Vol.104 (13), p.4188-4193

2004

Volltextzugriff (PDF)

Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha

The Journal of immunology (1950), 1999-07, Vol.163 (1), p.380-386

1999

Volltextzugriff (PDF)

Thalidomide as a novel therapeutic agent: new uses for an old product

Drug Discovery Today, 2005-01, Vol.10 (2), p.107-114

2005

Volltextzugriff (PDF)

Immunomodulatory analogs of thalidomide inhibit growth of Hs sultan cells and angiogenesis in vivo

Leukemia, 2003, Vol.17 (1), p.41-44

2003

Volltextzugriff (PDF)

Protective Antitumor Immunity Induced by a Costimulatory Thalidomide Analog in Conjunction with Whole Tumor Cell Vaccination Is Mediated by Increased Th1-Type Immunity

The Journal of immunology (1950), 2002-05, Vol.168 (10), p.4914-4919

2002

Volltextzugriff (PDF)

Clinical pharmacokinetics of thalidomide

Clinical pharmacokinetics, 2004-01, Vol.43 (5), p.311-327

2004

Volltextzugriff (PDF)

Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity

Cellular signalling, 2014-09, Vol.26 (9), p.2016-2029

2014

Volltextzugriff (PDF)

Thalidomide and its impact in dermatology

Seminars in cutaneous medicine and surgery, 1998-12, Vol.17 (4), p.231

Stirling, D I

1998

Volltextzugriff (PDF)

Thalidomide is distributed into human semen after oral dosing

Drug metabolism and disposition, 2001-10, Vol.29 (10), p.1355

2001

Volltextzugriff (PDF)

Effects of Thalidomide on Developmental, Peri- and Postnatal Function in Female New Zealand White Rabbits and Offspring

Toxicological sciences, 2004-10, Vol.81 (2), p.379-389

2004

Volltextzugriff (PDF)

Thalidomide analogs and PDE4 inhibition

Bioorganic & medicinal chemistry letters, 1998-10, Vol.8 (19), p.2669-2674

1998

Volltextzugriff (PDF)

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

Blood, 2001-07, Vol.98 (1), p.210-216

2001

Volltextzugriff (PDF)

Chiral inversion of the second generation IMiD™ CC-4047 (ACTIMID™) in human plasma and phosphate-buffered saline

Chirality (New York, N.Y.), 2003, Vol.15 (4), p.348-351

2003

Volltextzugriff (PDF)

Thalidomide Dose Proportionality Assessment following Single Doses to Healthy Subjects

Journal of clinical pharmacology, 2001-06, Vol.41 (6), p.662-667

2001

Volltextzugriff (PDF)

Safety profile of thalidomide after 53 weeks of oral administration in beagle dogs

Toxicological sciences, 2001, Vol.59 (1), p.160-168

2001

Volltextzugriff (PDF)

Protein Homeostatic Modulators, a Novel Class of Cereblon-Targeting Small Molecules As Potential Clinical Candidates in Multiple Myeloma

Blood, 2017, Vol.130, p.4418-4418

2017

Volltextzugriff (PDF)

Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers

British journal of cancer, 2004-03, Vol.90 (5), p.955-961

2004

Volltextzugriff (PDF)

Effects of thalidomide on reproductive function and early embryonic development in male and female New Zealand white rabbits

Birth defects research. Part B. Developmental and reproductive toxicology, 2004-02, Vol.71 (1), p.1-16

2004

Volltextzugriff (PDF)

Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs

The Journal of pharmacology and experimental therapeutics, 2003-06, Vol.305 (3), p.1222

2003

Volltextzugriff (PDF)

Remodelling of the PDE4 cAMP phosphodiesterase isoform profile upon monocyte‐macrophage differentiation of human U937 cells

British journal of pharmacology, 2004-05, Vol.142 (2), p.339-351

2004

Volltextzugriff (PDF)

Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly

Leukemia research, 2006-07, Vol.30 (7), p.849-858

2006

Volltextzugriff (PDF)

The synthetic compound CC-5079 is a potent inhibitor of tubulin polymerization and tumor necrosis factor-α production with antitumor activity

Cancer research (Chicago, Ill.), 2006-01, Vol.66 (2), p.951-959

2006

Volltextzugriff (PDF)

1 – 25 von 85

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(80)
Mit Volltextzugriff
(73)

Publikationsform

Sprache

Englisch
(84)
Japanisch
(18)
Latein
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(67)
Life Sciences & Biomedicine
(58)
Humans
(39)
Biological And Medical Sciences
(33)
Medical Sciences
(30)
Pharmacology. Drug Treatments
(24)
Animals
(21)
Female
(20)
Male
(19)
Thalidomide - Analogs & Derivatives
(18)
Pharmacology & Pharmacy
(16)
Thalidomide - Pharmacology
(14)
Thalidomide
(12)
Dose-Response Relationship, Drug
(11)
Oncology
(10)
Physical Sciences
(9)
Adult
(8)
Hematology
(8)
Mice
(8)
Thalidomide - Therapeutic Use
(8)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Apremilast, a cAMP phosphodiesterase‐4 inhibitor, demonstrates anti‐inflammatory activity in vitro and in a model of psoriasis

Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications

Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma

Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha

Thalidomide as a novel therapeutic agent: new uses for an old product

Immunomodulatory analogs of thalidomide inhibit growth of Hs sultan cells and angiogenesis in vivo

Protective Antitumor Immunity Induced by a Costimulatory Thalidomide Analog in Conjunction with Whole Tumor Cell Vaccination Is Mediated by Increased Th1-Type Immunity

Clinical pharmacokinetics of thalidomide

Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity

Thalidomide and its impact in dermatology

Thalidomide is distributed into human semen after oral dosing

Effects of Thalidomide on Developmental, Peri- and Postnatal Function in Female New Zealand White Rabbits and Offspring

Thalidomide analogs and PDE4 inhibition

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

Chiral inversion of the second generation IMiD™ CC-4047 (ACTIMID™) in human plasma and phosphate-buffered saline

Thalidomide Dose Proportionality Assessment following Single Doses to Healthy Subjects

Safety profile of thalidomide after 53 weeks of oral administration in beagle dogs

Protein Homeostatic Modulators, a Novel Class of Cereblon-Targeting Small Molecules As Potential Clinical Candidates in Multiple Myeloma

Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers

Effects of thalidomide on reproductive function and early embryonic development in male and female New Zealand white rabbits

Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs

Remodelling of the PDE4 cAMP phosphodiesterase isoform profile upon monocyte‐macrophage differentiation of human U937 cells

Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly

The synthetic compound CC-5079 is a potent inhibitor of tubulin polymerization and tumor necrosis factor-α production with antitumor activity

Suchergebnisse filtern